Tokyo, Jan. 28 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060476) titled 'A Multicenter Retrospective Study on the Efficacy and Safety of First-Line Treatments (Nivolumab plus Cabozantinib and Pembrolizumab plus Lenvatinib) for Advanced/Metastatic Renal Cell Carcinoma' on Jan. 27.
Study Type:
Observational
Primary Sponsor:
Institute - Institute of Science Tokyo
Condition:
Condition - Renal Cell Carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To explore the efficacy and safety of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib as optimal first-line treatments for patients with advanced or metastatic renal cell...